Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on formulation in the treatment of feline aelurostrongylosis.
The objective of the present study was to evaluate the efficacy and safety of the antiparasitic spot-on formulation containing imidacloprid 10%/moxidectin 1% (Advocate, Bayer) in the treatment of natural feline infection with the lungworm Aelurostrongylus abstrusus (Nematoda, Strongylida). The efficacy of Advocate administered once was tested in comparison to a control oral formulation containing fenbendazole 18.75% (Panacur Intervet) administered over three consecutive days based on larvae per gramme of faeces (LPG), measured on days 28 +/- 2 following treatment and compared to counts on days -6 to -2. In total 24 cats treated either with Advocate (n = 12) or with Panacur (n = 12) were included. Mean LPG postbaseline (days 28 +/- 2) were low in both treatment groups, i.e., 0 LPG for Advocate and 1.3 LPG for Panacur. Reduction of post-baseline larval counts showed Advocate (100% reduction) to be superior in efficacy compared to the control product (99.29% reduction). No treated animals showed adverse events. This trial demonstrated that both Advocate spot-on formulation and Panacur oral paste are safe and effective in the treatment of aelurostrongylosis in cats. Future practical perspectives in feline medicine and the major advantages of the spot-on product compared to the oral paste are discussed.
Traversa
Donato
D
Department of Comparative Biomedical Sciences, Faculty of Veterinary Medicine, Teramo, Italy. dtraversa@unite.it
Di Cesare
Angela
A
Milillo
Piermarino
P
Lohr
Beate
B
Iorio
Raffaella
R
Pampurini
Fabrizio
F
Schaper
Roland
R
Paoletti
Barbara
B
Heine
Josef
J
D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000469:parasitology; D002415:Cats; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005243:Feces / Q000469:parasitology; D005273:Fenbendazole / Q000009:adverse effects / Q000627:therapeutic use; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007814:Larva / Q000187:drug effects; D018942:Macrolides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008681:Metastrongyloidea / Q000187:drug effects*; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017206:Strongylida Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D016896:Treatment Outcome
D000871:Anthelmintics; D007093:Imidazoles; D018942:Macrolides; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; D005273:Fenbendazole; C027837:moxidectin